Here's a recap of our exciting October at Generation Bio! At the ESGCT 31st Annual Congress, we presented new preclinical data on our cell-targeted lipid nanoparticle (ctLNP) platform. In a non-human primate study conducted as part of our?collaboration?with @Moderna, Inc., a T cell ctLNP delivered mRNA to a majority of circulating T cells, with minimal biodistribution to other organs. This selective delivery to T cells in NHPs marks a significant advancement in our pursuit of in vivo genetic medicines. Stay tuned for more updates on our innovative genetic medicine research! #Biotech #GeneticMedicine #ESGCT2024 To learn more, visit the Scientific Presentations page on our website: https://lnkd.in/eDnPmsRK
Generation Bio
生物技术研究
Cambridge，Massachusetts 12,683 位关注者
We’re pushing the limits of genetic medicine. And our goal is no limits.
关于我们
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel immune-quiet DNA called iqDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce iqDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
- 网站
-
https://www.generationbio.com
Generation Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2016
- 领域
- Biotechnology、Rare Disease、Gene Therapy、LNPs、DNA和Non-Viral Gene Therapy
地点
-
主要
获取路线
301 Binney Street
4th Floor
US，Massachusetts，Cambridge，02142
Generation Bio员工
动态
-
Congratulations to Generation Bio Sr. Scientist Anthony Dawson for his presentation at the Cell & Gene Therapy International / BioProcess International Conference last week! Anthony discussed our Rapid Enzymatic Synthesis (RES) process, which is designed to significantly improve the speed, quality, and scalability of DNA manufacturing compared to traditional cell-based methods. If you missed it, you can check out the slides from Anthony's presentation on our website: https://lnkd.in/eDnPmsRK #BioProcessInternational?#BPI2024 #CGT2024
Our scientific presentations
https://generationbio.com